VTAK: רווח נקי למניה (EPS TTM) Catheter Precision

Catheter Precision's experienced management is actively implementing systems in US hospitals, developing synergy with cardiac centers through the integration of VIVO software for arrhythmia treatment. This 12-month EPS chart demonstrates the strategy's effectiveness, where -7.40 determines the current value of the metric. However, logistics disruptions in electronics supplies and export sanctions on medical equipment are constraining revenue growth.

Analyzing real business returns is critical for capital protection amid uncertainty. This indicator measures net profit distributed per share annually, neutralizing short-term volatility. By analyzing the rolling annual earnings per share, an investor assesses the impact of cost inflation on the bottom line. For Catheter Precision (VTAK), this trend reflects strained financial health. Low commercialization rates for cardiac systems make this metric sensitive to any operational expenses.